1. Home
  2. MEI vs GLUE Comparison

MEI vs GLUE Comparison

Compare MEI & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MEI
  • GLUE
  • Stock Information
  • Founded
  • MEI 1946
  • GLUE 2019
  • Country
  • MEI United States
  • GLUE United States
  • Employees
  • MEI N/A
  • GLUE N/A
  • Industry
  • MEI Electrical Products
  • GLUE Biotechnology: Pharmaceutical Preparations
  • Sector
  • MEI Technology
  • GLUE Health Care
  • Exchange
  • MEI Nasdaq
  • GLUE Nasdaq
  • Market Cap
  • MEI 231.0M
  • GLUE 351.2M
  • IPO Year
  • MEI N/A
  • GLUE 2021
  • Fundamental
  • Price
  • MEI $7.66
  • GLUE $4.80
  • Analyst Decision
  • MEI Buy
  • GLUE Buy
  • Analyst Count
  • MEI 2
  • GLUE 2
  • Target Price
  • MEI $10.50
  • GLUE $13.50
  • AVG Volume (30 Days)
  • MEI 404.9K
  • GLUE 369.2K
  • Earning Date
  • MEI 09-03-2025
  • GLUE 08-07-2025
  • Dividend Yield
  • MEI 3.62%
  • GLUE N/A
  • EPS Growth
  • MEI N/A
  • GLUE N/A
  • EPS
  • MEI N/A
  • GLUE 0.29
  • Revenue
  • MEI $1,048,100,000.00
  • GLUE $177,986,000.00
  • Revenue This Year
  • MEI N/A
  • GLUE $83.76
  • Revenue Next Year
  • MEI $0.44
  • GLUE N/A
  • P/E Ratio
  • MEI N/A
  • GLUE $16.32
  • Revenue Growth
  • MEI N/A
  • GLUE 2990.57
  • 52 Week Low
  • MEI $5.08
  • GLUE $3.50
  • 52 Week High
  • MEI $17.45
  • GLUE $12.40
  • Technical
  • Relative Strength Index (RSI)
  • MEI 63.37
  • GLUE 51.69
  • Support Level
  • MEI $6.52
  • GLUE $4.54
  • Resistance Level
  • MEI $7.83
  • GLUE $4.93
  • Average True Range (ATR)
  • MEI 0.28
  • GLUE 0.21
  • MACD
  • MEI 0.18
  • GLUE 0.06
  • Stochastic Oscillator
  • MEI 90.14
  • GLUE 81.43

About MEI Methode Electronics Inc.

Methode Electronics Inc supplier of custom-engineered solutions with sales, engineering, and manufacturing locations in North America, Europe, the Middle East, and Asia. It designs, engineers, and produces mechatronic products for Original Equipment Manufacturers (OEMs) utilizing a broad range of technologies for user interface, light-emitting diode (LED) lighting systems, power distribution, and sensor applications. The firm is organized into various business segments: Automotive, Industrial, Interface, and Medical. The Automotive segment, which generates maximum revenue, supplies electronic and electro-mechanical devices and related products to automobiles, including overhead and center consoles, hidden and ergonomic switches, insert molded components, LED-based lighting, and sensors.

About GLUE Monte Rosa Therapeutics Inc.

Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.

Share on Social Networks: